A First-In-Human Study of ARO-033 in Adult Participants

NCT07662096 ↗

Phase 1 Not yet recruiting 42 enrolled Arrowhead Pharmaceuticals

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-033 compared to placebo in adult normal healthy volunteers (NHVs).

Timeline

Start: 2026-06-22
Primary completion: 2027-07-18
Completion: 2027-07-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ARO-033	Unknown	—	Subcutaneous

Indications

No indication recorded.